SPIMACO manufactures first biosimilar product 'Enoxaparin' in Kingdom - Arab News

The Saudi Pharmaceutical Industries and Medical Supplies Company has launched the first commercial batch of Enoxaparin, to be fully manufactured in the Kingdom.

Khaled bin Saleh Al-Khattaf, CEO of SPIMACO Addwaeih, said that Enoxaparin, which is being manufactured at the company’s facility in Qassim, is the first biosimilar product to be produced in an integrated manner in the GCC by a national pharmaceutical company. The company began manufacturing after completing the technology transfer and localization process.

He said that pre-filled syringe Enoxaparin injections are low-molecular-weight heparin, used to treat blood clots and prevent their formation.

Al-Khattaf applauded the Kingdom’s ambitious strides toward becoming a global hub in the pharmaceutical industry. “This pioneering step reflects the nation’s commitment to leveraging our technological and scientific prowess, local talent, advanced infrastructure, and the unwavering support from our leadership. Our sustained investment is geared toward ensuring pharmaceutical security not just for the Kingdom but also for the wider region,” he added.

Looking ahead, SPIMACO is resolute in its mission to manufacture world-class quality medical preparations, bolstering the Kingdom’s position as a global stronghold in the pharmaceutical industry. “Our endeavors,” said Al-Khattaf, “align perfectly with Saudi Vision 2030, marking a significant milestone in our journey of leadership and innovation in the pharmaceutical sphere.” 

Adblock test (Why?)

Read Again https://news.google.com/rss/articles/CBMiNGh0dHBzOi8vd3d3LmFyYWJuZXdzLmNvbS9ub2RlLzIzNzQ3OTEvY29ycG9yYXRlLW5ld3PSAQA?oc=5

Bagikan Berita Ini